Skip to content

Harrow

US · HROW #3155 by market cap
30.41 -1.72 -5.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 8 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.3 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
60.71% +2.27pp
Institutions
256 -8
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund42.33%
Individual/Insider16.41%
Hedge Fund12.08%
VC/PE Fund3.00%
Private Company1.23%
Public Company1.21%
Government Pension Fund0.55%
Insurance Company0.22%
Family Office/Trust0.10%
Other22.88%

Top holders as of 2026-05-14

Mark Baum 7.98% · 3.00M sh
BlackRock 7.88% · 2.96M sh
Opaleye Management Inc. 5.61% · 2.11M sh
Daniel Kaufman 5.00% · 1.88M sh
Private Capital Management, LLC 4.26% · 1.60M sh
Vanguard Capital Management, LLC 3.72% · 1.39M sh
State Street Global Advisors 2.73% · 1.02M sh
Deep Track Capital, LP 2.58% · 969.00K sh
Geode Capital Management, LLC 2.27% · 852.94K sh
Andrew Boll 2.17% · 814.68K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 32 buys · 18 sells

NameRoleStake
Mark Baum CEO, Chairman of the Board & Founder 7.98%
Andrew Boll President, CFO & Chief Accounting Officer 2.17%
John Saharek Former President & CEO of Harrow’s ImprimisRx Division 1.25%
Adrienne Graves Independent Director 0.00%
Lauren Silvernail Independent Director 0.00%
Opaleye Management Inc. -- --
Amir Shojaei Chief Scientific Officer --
Perry Sternberg Lead Independent Director --
Randall Pollard Former Chief Accounting Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-13 Amir Shojaei Chief Scientific Officer Derivative Exercise and Sale -11,250 $35.96–40.00
2026-06-17 Adrienne Graves Independent Director Other Derivative Acquisition +5,248 --
2026-06-17 Lauren Silvernail Independent Director Other Derivative Acquisition +5,248 --
2026-06-17 Perry Sternberg Lead Independent Director Other Derivative Acquisition +5,248 --
2026-05-17 Adrienne Graves Independent Director Open Market Acquisition +1,000 $31.07
2026-05-17 Lauren Silvernail Independent Director Open Market Acquisition +1,000 $31.00
2026-05-14 Amir Shojaei Chief Scientific Officer Other Derivative Acquisition +10,000 --
2026-05-13 Mark Baum CEO, Chairman of the Board & Founder Open Market Acquisition +10,000 $30.20
2026-05-13 Andrew Boll President, CFO & Chief Accounting Officer Open Market Acquisition +3,500 $29.90
2026-03-03 Opaleye Management Inc. -- Open Market Disposition -198,572 $39.15–39.67
2026-02-26 Opaleye Management Inc. -- Open Market Disposition -5,000 $54.18
2026-01-05 Opaleye Management Inc. -- Open Market Disposition -20,000 $53.35
2025-12-11 Mark Baum CEO, Chairman of the Board & Founder Derivative Exercise and Sale -79,994 $3.95–47.06
2025-12-11 Mark Baum CEO, Chairman of the Board & Founder Derivative Exercise and Retained +100,006 $3.95
2025-12-11 Andrew Boll President, CFO & Chief Accounting Officer Derivative Exercise and Sale -26,665 $3.95–47.06
2025-12-11 Andrew Boll President, CFO & Chief Accounting Officer Derivative Exercise and Retained +33,335 $3.95
2025-08-31 Randall Pollard Former Chief Accounting Officer Other Derivative Acquisition +30,000 $39.00
2025-07-20 Mark Baum CEO, Chairman of the Board & Founder Derivative Exercise and Sale -313,338 $7.87–37.08
2025-07-20 Mark Baum CEO, Chairman of the Board & Founder Derivative Exercise and Retained +286,662 $7.87
2025-06-30 Mark Baum CEO, Chairman of the Board & Founder Other Derivative Acquisition +889,500 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Harrow discussion 0 comments

Add a comment